SynthesisHPB : the official journal of the International Hepato Pancreato Biliary Association2014
Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.
Synthesis in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers.Chinese medical journal · 2024Guideline
- Management of distal cholangiocarcinoma with arterial involvement: Systematic review and case series on the role of neoadjuvant therapy.World journal of gastrointestinal surgery · 2024Article
- Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.Cancers · 2024Review
- Article
- Article
- Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma.Journal of surgical oncology · 2023Article
- Preoperative Management of Perihilar Cholangiocarcinoma.Cancers · 2022Review
- Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma.World journal of gastroenterology · 2022Article
- Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.Visceral medicine · 2021Review
- Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study.Surgery today · 2020Article
- Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications.Current oncology reports · 2020Review
- Predictors of postoperative early recurrence of extrahepatic bile duct cancer.Surgery today · 2020Article
- Article
- The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer.Frontiers in oncology · 2020Review
- Management Strategies for Patients with Hilar Cholangiocarcinomas: Challenges and Solutions.Hepatic medicine : evidence and research · 2020Review
- Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging.Journal of the American College of Surgeons · 2018Article
- Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas.Journal of gastrointestinal oncology · 2018Article
- Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center.Annals of gastroenterological surgery · 2018Review
- Article
- Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience.Langenbeck's archives of surgery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHilar cholangiocarcinoma is a rare but highly lethal type of cancer. A minority of patients present with resectable disease. Surgery remains the only treatment modality offering a chance of long-term survival. Unresectable patients are typically offered palliative treatment. The aim of this systematic review was to summarize the evidence for neoadjuvant therapy followed by surgical resection in patients presenting with hilar cholangiocarcinoma.
methodsCochrane databases, Medline, PubMed and EMBASE were systematically searched to identify articles describing neoadjuvant therapy and surgical resection or re-assessment of resectability in patients with hilar cholangiocarcinoma. Included were all articles with original research. Study selection and data extraction were performed separately by two reviewers using a standardized protocol.
resultsFrom 732 articles 8 full text articles and 2 abstracts met the inclusion criteria. The 2 abstracts and 1 full text article were case reports, 3 articles were retrospective and 4 were prospective studies (2 phase I and 2 phase II studies). Photodynamic therapy, chemotherapy and radiation therapy were used in various indications in populations that included patients with hilar cholangiocarcinoma, some of which were primarily unresectable. Overall quality of articles was limited.
conclusionCurrent evidence suggests that neoadjuvant therapy in patients with unresectable hilar cholangiocarcinoma can be performed safely and in a selected group of patients can lead to subsequent surgical R0 resection. Surgical resection of downstaged patients should be assessed in properly designed phase II studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.